KANSAS CITY, Kan. and BOSTON, Nov. 11, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc . (NASDAQ: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it has appointed Craig Tooman to the position of Chief Financial Officer and named John C. Ayres as its General Counsel. Louise Mawhinney, former CFO of Aratana, will remain with the company.
Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics stated, "Aratana has grown considerably over the past year, having successfully completed our initial public offering in June and now, with the acquisition of Vet Therapeutics, becoming a commercial company. The appointments of Craig Tooman and John Ayres, both highly experienced commercial biopharmaceutical executives, will substantially enhance our strategy to establish Aratana as the industry leader in pet therapeutics. I'm extremely pleased to welcome Craig and John to our executive team and look forward to benefitting from their depth of knowledge and strategic vision."
A seasoned pharmaceutical executive with more than 20 years of industry experience, Mr. Tooman is widely versed in international finance, sales, market research, business intelligence, corporate strategy, M&A and investor relations. Immediately prior to his joining the executive team, Mr. Tooman had served as a Director and Chairman of Aratana's Audit Committee; he served as a member of the Board of Directors from March 2012 until his appointment as Chief Financial Officer. Mr. Tooman will also transition from his current position of CEO of Avanzar Medical, Inc., an oncology company, to focus on Aratana.
Previously, Mr. Tooman held executive positions at large pharmaceutical companies, including Pharmacia and Upjohn, and served as the CFO of Enzon Pharmaceuticals and Ikaria. While at ILEX Oncology, Mr. Tooman was a member of the executive team and was instrumental in transitioning the company from a CRO into a proprietary business responsible for developing successful oncology products. This strategic transformation ultimately led to ILEX being sold to Genzyme Corporation for $1.1 billion.Mr. Ayres joins Aratana from Amgen Inc. where he served as a member of the Corporate and Securities Law group for the world's largest independent biotechnology company. Within Amgen, Mr. Ayres advised the company's finance, human resources, investor relations and corporate communications groups. Prior to Amgen, Mr. Ayres was an associate at Latham & Watkins LLP where he specialized in public company counsel, including SEC compliance, initial public and follow-on stock offerings and mergers and acquisitions.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV